Oramed Pharmaceuticals Inc. balance sheet ORMP

Annual Quarterly

As of Jun 30, 2026, Oramed Pharmaceuticals Inc. had total assets of $369.6 million. Total assets were up 128.6% from a year earlier. Stockholders' equity was $317.5 million. It held $38.0 million in cash and investments against $733,000 of total debt, net cash of $37.2 million. The current ratio, current assets divided by current liabilities, was 4.98.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Aug 31, 2021	FY 2020 Aug 31, 2020	FY 2019 Aug 31, 2019	FY 2018 Aug 31, 2018	FY 2017 Aug 31, 2017	FY 2016 Aug 31, 2016
Assets
Cash	15 -3.5%	46	—	9	—	77 +300.3%	19 +479.6%	3 -33.4%	5 +25.9%	4 +1.6%	4 +21.6%
Short-term investments	1 -51.7%	5 +57.4%	3 -8.1%	58	4 -36.0%	6 -38.7%	10 +157.9%	4 -19.4%	5 +60.6%	3 +0.2%	3 +36.7%
Long-term investments	22	8 +363.3%	—	2 -53.4%	3 -59.7%	7 +70.4%	4 +203.3%	1 -53.5%	3 +29.5%	2 +305.8%	1 -43.6%
Cash and investments	38 +116.3%	60 +1038.2%	3 -73.1%	69 +1669.7%	6 -92.8%	90 +174.0%	33 +293.6%	8 -32.7%	12 +37.8%	9 +23.1%	7 +16.8%
Total current assets	53 -46.1%	133 -6.9%	143 -11.9%	163 +3.5%	157 +64.8%	95 +135.3%	41 +21.6%	33 +7.4%	31 +52.9%	20 -35.0%	31 +79.8%
Property and equipment, net	1 -17.5%	1 -16.0%	1 -20.0%	1 +7.1%	1 +105.3%	0 +301.0%	0 +312.5%	0 +41.2%	0 -5.6%	0 +12.5%	0 +45.5%
Total assets	370 +128.6%	231 +48.7%	155 -29.6%	221 +36.4%	162 +26.3%	128 +186.8%	45 +28.8%	35 -26.9%	47 +22.4%	39 -9.6%	43 +62.5%
Liabilities and equity
Accounts payable	0 -47.7%	0 -43.9%	1	—	—	—	—	—	—	—	—
Total current liabilities	11 +190.6%	19 +235.7%	6 -89.3%	53 +826.1%	6 -14.0%	7 +47.2%	5 -14.5%	5 +16.6%	5 -11.8%	5 +42.6%	4 +143.2%
Stockholders' equity	317 +106.7%	200 +36.6%	146 -10.7%	164 +7.9%	152 +31.1%	116 +252.1%	33 +69.5%	19 -37.7%	31 +61.7%	19 -26.5%	26 +5.5%
Debt
Debt due within a year	—	—	—	51	—	—	—	3	—	—	—
Long-term debt	—	—	—	—	0	—	—	10	—	—	—
Lease liabilities	1 -19.6%	1 +121.8%	0 -38.9%	1 -31.9%	1 +121.8%	0 +139.9%	0	—	—	—	—
Total debt	1 -19.6%	1 -98.4%	0 -38.9%	52 +5517.2%	1 +128.0%	0 +139.9%	0 -99.4%	12	—	—	—
Net cash	37 +123.7%	59 +227.7%	3 -74.8%	17 +473.5%	6 -93.8%	89 +174.2%	33 +910.0%	-4	—	—	—
Ratios
Current ratio	4.98x	6.98x	25.19x	3.06x	27.34x	14.27x	8.93x	6.28x	6.82x	3.93x	8.62x
Debt to equity	0.00x	0.00x	0.00x	0.32x	0.01x	0.00x	0.00x	0.64x	—	—	—
Return on equity	55.08%	32.07%	-13.03%	3.11%	—	-19.86%	-35.01%	-74.02%	-40.91%	-54.48%	-41.86%
Return on assets	47.31%	27.74%	-12.27%	2.31%	—	-17.96%	-25.79%	-41.41%	-26.85%	-27.07%	-25.60%
Book value per share	7.68	5.09	3.66	4.06	3.84	3.28	1.39	1.12	1.79	1.41	1.99

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: ORMP (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: New York, NY
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1176309
Former names: Integrated Security Technologies, Inc. (until Apr 10, 2006); IGUANA VENTURES LTD (until Jun 10, 2004)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.